Wade, R. Chad
Mkorombindo, Takudzwa
Ling, Sharon X.
Helgeson, Erika. S.
MacDonald, David M.
Pew, Krystle
Voelker, Helen
Bittner, Vera
Kunisaki, Ken M.
Lammi, Matthew R.
Dransfield, Mark. T.
Funding for this research was provided by:
U.S. Department of Defense (W81XWH-15-1-0705, W81XWH-15-1-0705, W81XWH-15-1-0705, W81XWH-15-1-0705, W81XWH-15-1-0705, W81XWH-15-1-0705, W81XWH-15-1-0705, W81XWH-15-1-0705)
Article History
Received: 18 May 2023
Accepted: 4 November 2023
First Online: 9 November 2023
Declarations
:
: The University of Alabama at Birmingham Institutional Review Board (IRB) approved the study procedures with subsequent review and adoption by each study site. Participants or legal guardians provided informed consent for the parent study, BLOCK-COPD (UAB IRB # 150609007), which included permission for use of data in subsequent analyses. Study procedures involving human participants/data was performed in accordance with the Declaration of Helsinki.
: Not applicable.
: ESH has received grant support from the National Institutes of Health and the Department of Defense and clinical trial support from Fisher & Paykel Healthcare; MTD reports grants from the American Lung Association, Department of Defense, and National Institutes of Health, consulting fees from AstraZeneca, GlaxoSmithKline, Novartis, Pulmonx, and Teva. The remaining authors have declared that no conflict of interest exists.